New combo strategy aims to delay hormone resistance in prostate cancer
NCT ID NCT06734130
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 27 times
Summary
This study tests whether giving hormone therapy and chemotherapy in an adaptive, on-and-off pattern can keep prostate cancer sensitive to hormone treatment longer. It involves 25 men with stage IV prostate cancer that still responds to hormones. The goal is to see if this approach delays the cancer from becoming resistant, potentially improving long-term control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION SENSITIVE PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Moffitt Caner Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.